Dianthus Therapeutics | MGTA - Net Income


Dianthus Therapeutics reported $-40.83M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
Alaunos Therapeutics USD -1.01M 153K Mar/2026
Avita Medical AUD -11.62M 1.7M Dec/2025
Celltrion KRW 8.82B 64.74M Mar/2026
Cspc Pharmaceutical CNY 370.72M 592.81M Dec/2025
Deva Holding AS TRY 583.98M 319.1M Sep/2023
Dianthus Therapeutics USD -40.83M 23.6M Mar/2026
Divis Laboratories Ltd INR 9.02B 1.51B Jun/2026
IQVIA Holdings USD 256M 18M Jun/2026
Kangmei Pharma CNY -16.56M 12.74M Mar/2026
Knight Therapeutics CAD -3.79M 8.83M Sep/2025
Laboratorios Farma EUR 103.69M 37.04M Dec/2023
Malin Corporation EUR -1.1M 2.2M Dec/2023
Medical Developments International AUD -226K 121K Dec/2025
Moderna USD -1.34B 517M Mar/2026
Neuren Pharmaceuticals AUD 15.4M 7.88M Dec/2025
Organigram Holdings CAD -921K 20.89M Mar/2026
Organon & Co USD 108M 38M Jun/2026
Ovoca Bio EUR 4.42M 5.19M Dec/2025
Pharma Mar EUR -972K 2.5M Jun/2026
Qiagen NV USD 103.4M 35.36M Jun/2026
Revvity USD 51.82M 11.1M Jun/2026
Sartorius EUR 65.9M 9.7M Jun/2026
Sino Biopharmaceutical CNY 3.39B 2.91B Jun/2025
Tectonic Therapeutic USD -25.24M 6.02M Mar/2026
Tilray USD -44.93M 44.61M Sep/2025
Viatris USD -118.8M 295.2M Jun/2026
Xeris Pharmaceuticals USD 2.23M 8.85M Mar/2026
Zealand Pharma A/S -394M 14.88M Mar/2026
Zz Pientze Pharmaceu CNY 349.49M 393.99M Jun/2026